This article is more than 5 years old. Information may no longer be current.
VIDEO: Artificial Intelligence Enterprise Gains Partner in Colon Cancer Screening Development
Click Here to Manage Email Alerts
WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, the founder of ai4gi Solutions Inc., a commercial joint venture between Satis Operations and Imagia that aims to design artificial intelligence for improved gastrointestinal cancer screening, announced a codevelopment agreement with Olympus.
“Artificial intelligence is really making huge changes in many of the spaces and is coming to medicine quite quickly, so the idea that we can do this with Olympus and bring it to a field that is close to my heart is very exciting for us and we're happy to begin,” Michael Byrne, MD (Cantab), MRCP, FRCPC, told Healio Gastroenterology and Liver Disease.
The goal of the ai4gi, in collaboration with Olympus, is apply artificial intelligence to medical image analysis for accurate and timely cancer detection and differentiation.
“The opportunity here is huge to improve endoscopic procedures, how we do colonoscopy for colon-cancer screening, and the benefits for patients going forward,” Byrne said.
Disclosure: Byrne is the founder of ai4gi Solutions Inc. and has an ownership interest in Satis Operations.